<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04108026</url>
  </required_header>
  <id_info>
    <org_study_id>IFCT-1802</org_study_id>
    <nct_id>NCT04108026</nct_id>
  </id_info>
  <brief_title>Immunotherapy in Patient With Poor General Condition</brief_title>
  <acronym>SAVIMMUNE</acronym>
  <official_title>A Phase II Single-arm Trial Evaluating Safety and Efficacy of Durvalumab in ECOG Performance Status 2-3, Treatment-naive, Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) and High PD-L1 Tumor Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intergroupe Francophone de Cancerologie Thoracique</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunotherapeutic approaches targeting immune checkpoint proteins PD-1/PD-L1 have recently&#xD;
      demonstrated clinical efficacy in several cancer types, and have changed the therapeutic&#xD;
      landscape in metastatic melanoma or non-small cell lung cancer (NSCLC).&#xD;
&#xD;
      The monoclonal anti-PD-1 antibody nivolumab has been registered by both FDA (Food and Drug&#xD;
      Administration) and EMA (European Medicine Agency), for metastatic NSCLC patients, after&#xD;
      failure of a prior platinum-based chemotherapy.&#xD;
&#xD;
      The approval was based on the results of phase III clinical trials in metastatic NSCLC. But&#xD;
      all the trials only enrolled patients with good general condition, PS (Performance Status) 0&#xD;
      or 1. However, the prevalence of poor PS patients at time of diagnosis is high in lung cancer&#xD;
      patients.&#xD;
&#xD;
      For patients with metastatic NSCLC and PS 3, there is no standard treatment except best&#xD;
      supportive care, since all trials that accrued unselected PS 3 patients fail to prove any&#xD;
      survival advantage, and most PS &gt;3 patients die within 2 to 4 months from diagnosis. Indeed,&#xD;
      these patients are currently excluded from clinical trials. Specific dedicated clinical&#xD;
      trials and treatment guidelines for this patient population are urgently needed, taking into&#xD;
      account for the high prevalence of such patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients experiencing Grade 3-5 Treatment Related Adverse Event at 8 weeks of durvalumab</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence, type and severity of adverse event</measure>
    <time_frame>From time of informed consent through treatment period (24 months) or up to 100 days post last dose of study treatment</time_frame>
    <description>The maximum grade will be summarized by frequency and proportion of total patients, by system organ class and NCI-CTC, Version 5.0 categories.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of patients with objective response or stable disease according to RECIST 1.1 in the intent to treat population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate according to BICR (Blinded Independent Central Review) and investigators</measure>
    <time_frame>8 weeks (confirmed at 16 weeks)</time_frame>
    <description>Percentage of patients with objective response according to RECIST 1.1 in the intent to treat population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Time between the date of durvalumab initiation and the first date of documented progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Time between the date of durvalumab initiation and the date of death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance status improvement rate</measure>
    <time_frame>From time of randomisation through treatment period (24 months)</time_frame>
    <description>Proportion of per-protocol patients whose PS during durvalumab treatment was improved from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Quality of life</measure>
    <time_frame>From time of randomisation through treatment period (24 months)</time_frame>
    <description>EORTC QLQ-C30 +LC13 (Qualify of Life Questionnaire C30 + Lung Cancer 13) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Centrally-assessed PD-L1 tumor expression Prognostic and predictive value</measure>
    <time_frame>Baseline only</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Quality of life</measure>
    <time_frame>From time of randomisation through treatment period (24 months)</time_frame>
    <description>EQ-5D (EuroQol 5 Dimensions) questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Non-small Cell Lung Cancer Stage IV</condition>
  <arm_group>
    <arm_group_label>Immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab 1500 mg every 4 weeks until the progression of disease, discontinuation due to toxicity or withdrawal of consent, for a maximum duration of 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>1500 mg IV every 4 weeks</description>
    <arm_group_label>Immunotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must have signed and dated an IEC (Independent Ethic Committee) approved&#xD;
             written informed consent form in accordance with regulatory and institutional&#xD;
             guidelines. This must be obtained before the performance of any protocol related&#xD;
             procedures that are not part of normal subject care.&#xD;
&#xD;
             Subjects must be willing and able to comply with scheduled visits, treatment schedule,&#xD;
             and laboratory testing.&#xD;
&#xD;
          2. Histologically or cytologically-proven NSCLC (squamous or non-squamous). If the&#xD;
             diagnosis is cytologically-proven, sufficient material is necessary with at least 100&#xD;
             tumor cells evaluated for PD-L1 IHC (Immunohistochemistry).&#xD;
&#xD;
          3. PD-L1 expression ≥25% of tumor cells as assessed by the local pathology laboratory&#xD;
             using protocols validated.&#xD;
&#xD;
          4. Available tumor samples for centralized PD-L1 immunohistochemistry analysis.&#xD;
&#xD;
          5. No EGFR (Epidermal Growth Factor Receptor) mutation and no ALK(Anaplasic Lymphoma&#xD;
             Kinase) gene rearrangement.&#xD;
&#xD;
          6. Stage IV (8th classification TNM) M1a or M1b or M1c.&#xD;
&#xD;
          7. ECOG (Eastern Cooperative Oncology Group) PS = 2 (in the first step) or 3 (in the&#xD;
             second step) despite optimal symptomatic treatment.&#xD;
&#xD;
          8. Body weight &gt;30kg&#xD;
&#xD;
          9. No prior systemic anticancer therapy (chemotherapy, immunotherapy including&#xD;
             durvalumab, or EGFR or ALK inhibitors) given as primary therapy for advanced or&#xD;
             metastatic disease. Neoadjuvant or adjuvant chemotherapy is not considered as&#xD;
             chemotherapy for advanced or metastatic disease.&#xD;
&#xD;
         10. Limited field of radiation for palliation within 2 weeks of the first dose of&#xD;
             durvalumab is allowed, provided the lung is not in the radiation field and irradiated&#xD;
             lesion(s) cannot be used as target lesions.&#xD;
&#xD;
         11. Age 18-75 years.&#xD;
&#xD;
         12. Measurable tumor disease by CT per Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST) 1.1.&#xD;
&#xD;
         13. Life expectancy &gt; 8 weeks according to the investigator opinion.&#xD;
&#xD;
         14. Adequate biological functions:&#xD;
&#xD;
             neutrophils ≥ 1500/mm3 ; platelets ≥ 75 000/mm3 ; Hemoglobin ≥ 9 g/dL ; Creatinine&#xD;
             Clearance &gt; 40 mL/min , AST and ALT ≤ 2,5 ULN unless liver metastases are present, AST&#xD;
             (aspartate aminotransferase) and ALT (alanine aminotransferase) ≤ 5 x ULN, serum&#xD;
             bilirubin ≤ 1.5 x ULN except for patients with proved, Gilbert syndrome (≤ 5 x ULN) or&#xD;
             patients with hepatic metastases (≤ 3 x ULN).&#xD;
&#xD;
         15. Other investigations detailed in Section 5 must have been performed within the&#xD;
             timelines indicated.&#xD;
&#xD;
         16. Protocol treatment is to begin within 7 days of patient inclusion.&#xD;
&#xD;
         17. Evidence of post-menopausal status or negative urinary or serum pregnancy test for&#xD;
             female pre-menopausal patients. Women will be considered post-menopausal if they have&#xD;
             been amenorrheic for 12 months without an alternative medical cause. The following&#xD;
             age-specific requirements apply:&#xD;
&#xD;
               -  Women &lt;50 years of age would be considered post-menopausal if they have been&#xD;
                  amenorrheic for 12 months or more following cessation of exogenous hormonal&#xD;
                  treatments and if they have luteinizing hormone and follicle-stimulating hormone&#xD;
                  levels in the post-menopausal range for the institution or underwent surgical&#xD;
                  sterilization (bilateral oophorectomy or hysterectomy).&#xD;
&#xD;
               -  Women ≥50 years of age would be considered post-menopausal if they have been&#xD;
                  amenorrheic for 12 months or more following cessation of all exogenous hormonal&#xD;
                  treatments, had radiation-induced menopause with last menses &gt;1 year ago, had&#xD;
                  chemotherapy-induced menopause with last menses &gt;1 year ago, or underwent&#xD;
                  surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or&#xD;
                  hysterectomy).&#xD;
&#xD;
         18. Females of childbearing potential who are sexually active with a nonsterilized male&#xD;
             partner or men who are sexually active with women of childbearing potential must use a&#xD;
             highly effective method of contraception prior the first dose of investigational&#xD;
             product, and must agree to continue using such precautions for 90 days after the final&#xD;
             dose of investigational product. Periodic abstinence, the rhythm method, and the&#xD;
             withdrawal method are not acceptable methods of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pure or combined SCLC.&#xD;
&#xD;
          2. Known HER2 (Human Epidermal Growth Factor Receptor), B-Raf, activating tumor&#xD;
             mutations, or exon 14 c-MET splice mutations (mesenchymal-epithelial transition), or&#xD;
             known ROS1 gene rearrangement.&#xD;
&#xD;
          3. Asymptomatic or symptomatic brain metastasis.&#xD;
&#xD;
          4. Carcinomatous meningitis.&#xD;
&#xD;
          5. Active or prior documented autoimmune or inflammatory disorders (including&#xD;
             inflammatory bowel disease [e.g., colitis or Crohn's disease], systemic lupus&#xD;
             erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with&#xD;
             polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The&#xD;
             following are exceptions to this criterion:&#xD;
&#xD;
               -  Patients with vitiligo or alopecia&#xD;
&#xD;
               -  Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on&#xD;
                  hormone replacement&#xD;
&#xD;
               -  Any chronic skin condition that does not require systemic therapy&#xD;
&#xD;
               -  Patients without active disease in the last 5 years may be included but only&#xD;
                  after consultation with IFCT&#xD;
&#xD;
               -  Patients with celiac disease controlled by diet alone&#xD;
&#xD;
          6. Immunosuppressive treatment including systemic treatment with corticosteroids with&#xD;
             greater dose than 10 mg prednisone equivalent daily, within 15 days before enrollment.&#xD;
             Inhaled, nasal or topic corticosteroids are allowed.&#xD;
&#xD;
          7. History of allogenic organ transplantation.&#xD;
&#xD;
          8. Stage 4 (very severe, FEV1 (forced expiratory volume at one second) &lt;30% predicted)&#xD;
             chronic obstructive pulmonary disease (COPD) according to GOLD classification.&#xD;
&#xD;
          9. NYHA (New York Heart Association) class 4 chronic heart failure&#xD;
&#xD;
         10. Pre-existing interstitial lung.&#xD;
&#xD;
         11. History of another primary malignancy except for :&#xD;
&#xD;
               -  Malignancy treated with curative intent and with no known active disease ≥2 years&#xD;
                  before the first dose of IP (Investigational Product) and of low potential risk&#xD;
                  for recurrence&#xD;
&#xD;
               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease&#xD;
&#xD;
               -  Adequately treated carcinoma in situ without evidence of residual disease&#xD;
                  Patients with a prostate adenocarcinoma history within the previous 5 years could&#xD;
                  be included in case of localized prostate cancer.&#xD;
&#xD;
         12. Living attenuated vaccine received within the 30 previous days.&#xD;
&#xD;
         13. Received any other experimental treatment or participation to any other therapeutic&#xD;
             clinical trial.&#xD;
&#xD;
         14. Known allergy or hypersensitivity to any of the study drug or any of the study drug&#xD;
             excipients.&#xD;
&#xD;
         15. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment.&#xD;
             Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone&#xD;
             replacement therapy) is acceptable.&#xD;
&#xD;
         16. Major surgical procedure within 28 days prior to the first dose of IP or planned&#xD;
             surgical procedure during treatment.&#xD;
&#xD;
         17. Uncontrolled intercurrent illness, including but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic&#xD;
             gastrointestinal conditions associated with diarrhea, or psychiatric illness/social&#xD;
             situations that would limit compliance with study requirement, substantially increase&#xD;
             risk of incurring AEs (Adverse Events) or compromise the ability of the patient to&#xD;
             give written informed consent.&#xD;
&#xD;
         18. Active infection including tuberculosis, hepatitis B (known positive HBV surface&#xD;
             antigen (HBsAg) result) and hepatitis C,. Patients with a past or resolved HBV&#xD;
             infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence&#xD;
             of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible&#xD;
             only if polymerase chain reaction is negative for HCV RNA. History of active&#xD;
             tuberculosis or evident primo-infection for which there is no record or evidence of an&#xD;
             active anti-tuberculous treatment (please consult IFCT in case of doubt).&#xD;
&#xD;
         19. Patient with human immunodeficiency virus (positive HIV ½ antibodies)&#xD;
&#xD;
         20. Any condition that, in the opinion of investigator, could compromise the adherence to&#xD;
             treatment and follow-up.&#xD;
&#xD;
         21. Mental illness or psychological condition, which in the opinion of investigator could&#xD;
             compromise the expression of the informed consent.&#xD;
&#xD;
         22. No public health insurance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie GOUNANT</last_name>
    <role>Study Chair</role>
    <affiliation>AP-HP Hôpital Bichat-Claude Bernard</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael DURUISSEAUX</last_name>
    <role>Study Chair</role>
    <affiliation>Hospices Civils de Lyon - Hôpital Louis Pradel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Operations</last_name>
    <phone>0156811046</phone>
    <phone_ext>33</phone_ext>
    <email>Contact@ifct.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Besançon - CHU</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie WESTEEL</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré - Pneumologie</name>
      <address>
        <city>Boulogne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne GIROUX-LEPRIEUR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caen - CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannick MADELAINE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel MOREAU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis MORO-SIBILOT</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier - Pneumologie</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Pinquié, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier DHALLUIN, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HM Hopital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice Barlesi, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montpellier - CHRU</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit ROCH, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GRH Mulhouse Sud-Alsace</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier DEBIEUVRE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nancy - Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle CLEMENT-DUCHENE, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nantes - ICO Site René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine HIRET, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR d'Orléans La Source</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrien DIXMIER</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Hopital Tenon - Pneumologie</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Cadranel, Pr</last_name>
      <phone>+33.1.56.01.65.31</phone>
      <email>contact@ifct.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques Cadranel, pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paris - APHP Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Gounant, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
    <investigator>
      <last_name>Valérie Gounant, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paris - Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Ange MASSIANI, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyon - URCOT</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Duruisseaux, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François-Roger VANEL</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Pneumologie</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Rabeau, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Tours - Pneumologie</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine CARMIER</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.ifct.fr</url>
    <description>IFCT website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IFCT</keyword>
  <keyword>Savimmune</keyword>
  <keyword>Non small cell Lung Cancer</keyword>
  <keyword>PS</keyword>
  <keyword>Poor General condition</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Durvalumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

